Objective To compare the efficacy of TightRope loop plate and Endobutton plate in the treatment of acromioclavicular joint dislocation.Methods A retrospective analysis was conducted on 94 patients with acromioclavicular joint dislocation who were treated at this center from March 2021 to February 2023.They were divided into two groups based on different admission date.The Group E(n =47)received Endobutton plate treatment between March 2021 and February 2022,while the Group T(n =47)received TightRope loop plate treatment between March 2022 and February 2023.At the last follow-up,the perioperative indicators,Visual Analogue Scale(VAS),Constant-Murley shoulder joint function scores,and surgical complications were compared between the two groups.Results The surgical time,intraoperative bleeding,incision length,and VAS scores at 7 days after surgery in the Group T were shorter or lower than those in the Group E(P<0.05).There were no statistical differences in the incidence of perioperative nerve injury,internal fixation displacement,clavicle fracture,vascular injury,and infection between the two groups(P>0.05).The subjective and objective scores of Constant-Murley shoulder joint function in both groups at9 months after surgery showed significant improvement compared to preoperative scores(all P =0.000).There was no significant difference in the subjective and objective scores of Constant-Murley shoulder joint function between the two groups at 9 months after surgery(P>0.05).Conclusions The treatment of acromioclavicular joint dislocation with TightRope loop plate ot or Endobutton plate has a significant effect and can effectively improve shoulder joint function.Compared with Endobutton plate,use of TightRope loop plate has minor surgical trauma,less bleeding,and significantly reduced postoperative pain,being more conducive to early functional exercise for patients.

Objective To investigate the level of plasma MALAT1 in breast cancer(BC)patients and its clinical significance.Methods The expression levels of MALAT1 different fragments were detected in plasma from 10 healthy controls.The expressions of GAPDH and MALAT1 of plasma samples collected from 102 preoperative breast cancer patients,64 postoperative breast cancer patients,47 breast benign tumor patients and 50 healthy controls were determined by RT-qPCR.The potential association between plasma GAPDH level and cases′clinicopathologic features was analyzed to evaluate the stability of GAPDH. Receiver operating characteristic(ROC)curve was constructed to evaluate the diagnostic efficiency of MALAT1,CA153 and CEA for breast cancer.Meanwhile, the association between MALAT1 level and the clinicopathologic features and the expressions of MALAT 1 between preoperative and postoperative BC patients were analyzed.T-test and one-factor ANOVA test were used for normal distribution of quantitative data.The rank sum test was used for non-normal distribution of data.Results GAPDH level was stable in female plasma and was not affected by age and pathology(P>0.05).GAPDH can be used as a reference for plasma lncRNA detection.The levels of different MALAT1 fragments were inconsistent(χ2=27.042,P<0.001).Levels of MALAT1 were significantly elevated in preoperative BC patients[5.58(2.17-12.34)] compared with breast benign tumor patients and healthy controls[1.08(0.61 -2.58)(Z=6.209,P<0.001),1.63(0.98 -3.51)(Z=4.871,P<0.001)].However, there was no significantly difference between breast benign tumor patients and healthy controls(Z=-1.675,P=0.094).The MALAT1 levels of low grade patients(gradeI and II)were higher than those of breast benign tumor patients(Z=5.593,P<0.001).The relative expression of MALAT1 in postoperative plasma was significantly reduced(Z=-2.248,P=0.025).Areas under the ROC curve of MALAT1,CA153 and CEA were 0.744,0.619 and 0.553 respectively.The sensitivity and specificity were 54.1%,60.0%,70.0% and 86.3%,66.7%, 44.1%respectively.The levels of MALAT1 were associated with TNM stage(Z=-1.982,P=0.047), lymph node metastasis(Z=-2.186,P=0.029)and tumor differentiation(Z=-2.435,P=0.015). Conclusion The expressions of MALAT1 were highly elevated in BC patients.Plasma MALAT1 may be an important biomarker for the diagnosis of breast cancer.

Glycolytic metabolism enzymes have been implicated in the immunometabolism field through changes in metabolic status. PGK1 is a catalytic enzyme in the glycolytic pathway. Here, we set up a high-throughput screen platform to identify PGK1 inhibitors. DC-PGKI is an ATP-competitive inhibitor of PGK1 with an affinity of K _d = 99.08 nmol/L. DC-PGKI stabilizes PGK1 in vitro and in vivo, and suppresses both glycolytic activity and the kinase function of PGK1. In addition, DC-PGKI unveils that PGK1 regulates production of IL-1β and IL-6 in LPS-stimulated macrophages. Mechanistically, inhibition of PGK1 with DC-PGKI results in NRF2 (nuclear factor-erythroid factor 2-related factor 2, NFE2L2) accumulation, then NRF2 translocates to the nucleus and binds to the proximity region of Il-1β and Il-6 genes, and inhibits LPS-induced expression of these genes. DC-PGKI ameliorates colitis in the dextran sulfate sodium (DSS)-induced colitis mouse model. These data support PGK1 as a regulator of macrophages and suggest potential utility of PGK1 inhibitors in the treatment of inflammatory bowel disease.